Clinical Trial: NCT01430390
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT organ SCT or for patients who are at high risk for relapse of their B cell leukemia or lymphoma.
Official Title
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Conditions
Acute Lymphocytic Leukemia, Lymphoma
Intervention / Treatment
- Biological: Biological/Genetically Modified T cells
- Drug: Cyclophosphamide-based chemotherapy
Other Study ID Numbers
- 11-038
Start Date (Actual)
2011-09
Primary Completion Date (Estimated)
2027-09
Study Completion Date (Estimated)
2027-09
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT organ SCT or for patients who are at high risk for relapse of their B cell leukemia or lymphoma.
Official Title
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Conditions
Acute Lymphocytic Leukemia, Lymphoma
Intervention / Treatment
- Biological: Biological/Genetically Modified T cells
- Drug: Cyclophosphamide-based chemotherapy
Other Study ID Numbers
- 11-038
Start Date (Actual)
2011-09
Primary Completion Date (Estimated)
2027-09
Study Completion Date (Estimated)
2027-09
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 1